Kazuya Kuramoto
Kyoto, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Antiproliferative effect of selexipag active metabolite MRE-269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension.
Journal: Pulmonary circulation
Published: December 21, 2022
Improving Right Ventricular Function by Increasing BMP Signaling with FK506.
Journal: American journal of respiratory cell and molecular biology
Published: May 03, 2021
Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of pulmonary artery de-banding.
Journal: Cardiovascular research
Published: March 27, 2019
FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.
Journal: American journal of respiratory and critical care medicine
Published: August 15, 2018
NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways.
Journal: Blood cancer journal
Published: November 26, 2017
A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
Journal: European journal of pharmacology
Published: August 08, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026